Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio, Inc. (NYSE: ANVS) generates a steady flow of news as a late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). This news page aggregates announcements that reflect the company’s progress in clinical development, regulatory interactions, scientific presentations, and corporate activity.
Readers can follow updates on buntanetap, Annovis’ lead drug candidate, across multiple indications. News items include milestones from the pivotal Phase 3 trial in early Alzheimer’s disease, such as activation of clinical sites, enrollment status, and timing of key readouts. In Parkinson’s disease, press releases cover Phase 3 data analyses, biomarker findings related to amyloid co‑pathology and tau measures, and the design and objectives of the Open-Label Extension study that evaluates long-term safety and efficacy in diverse patient cohorts, including those receiving deep brain stimulation.
Company news also highlights regulatory developments, including scheduled FDA meetings to discuss the pathway for Parkinson’s disease dementia and confirmation of alignment on Phase 3 Alzheimer’s study design and endpoints. Scientific communications feature presentations at major conferences focused on Parkinson’s disease and Alzheimer’s clinical trials, where Annovis shares biomarker data, cross-study comparisons, and analyses of cognitive outcomes in patients with defined biomarker profiles.
In addition to clinical and scientific updates, this feed includes corporate events such as earnings releases, capital raises through registered direct offerings, leadership changes, and NYSE listing compliance disclosures. Investors, clinicians, and other stakeholders can use this page to track how Annovis communicates its trial progress, financial condition, and strategic priorities over time. For those following ANVS stock or the development of buntanetap in Alzheimer’s and Parkinson’s disease, this news stream provides a consolidated view of the company’s publicly reported milestones.
Annovis (NYSE: ANVS) entered into definitive agreements to sell an aggregate of 4,000,000 shares of common stock (or pre-funded warrants) at $1.50 per share in a registered direct offering, with expected gross proceeds of approximately $6 million. Closing is expected on or about October 13, 2025, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The company intends to use net proceeds for working capital and general corporate purposes. The offering is being made under a shelf registration (Form S-3, Reg. No. 333-276814) with a prospectus supplement to be filed with the SEC.
Annovis (NYSE: ANVS) reported novel biomarker results from its Phase 2/3 Alzheimer's study (NCT05686044) showing that buntanetap reduced inflammatory markers IL-5, IL-6, S100A12, IFN-γ, IGF1R and lowered NFL after three months. Responses were seen in all patients with positive pTau217, including mild and moderate stages. Company cites prior cognitive benefit in mild AD and notes buntanetap is being evaluated in a pivotal Phase 3 early AD trial (NCT06709014) with a 6-month symptomatic readout and an 18-month disease-modification readout. Full biomarker data will be presented at CTAD Dec 1-4, 2025.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, has appointed Mark Guerin as Chief Financial Officer. Guerin brings significant biopharma financial leadership experience, notably serving as CFO at Onconova Therapeutics (now Traws Pharma) where he managed multiple financing transactions.
The appointment comes at a crucial time as Annovis's lead drug candidate buntanetap advances through late-stage clinical development for Alzheimer's and Parkinson's disease. Guerin's extensive background includes roles at Cardiokine and Barrier Therapeutics, where he oversaw key financial operations including IPOs and corporate transactions.
[ "Appointment of experienced CFO with strong track record in biopharma financing", "Lead drug buntanetap showing promise in late-stage clinical development", "Strategic timing of CFO appointment ahead of potential commercialization phase" ]Annovis Bio (NYSE:ANVS) announced a peer-reviewed publication in Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap, their lead drug candidate for neurodegenerative diseases. The new dihydrate crystal form demonstrates enhanced stability while maintaining the same pharmacokinetic profile and metabolism as the original anhydrous form.
The crystal buntanetap is currently being utilized in a Phase 3 clinical trial for early Alzheimer's disease, with key readouts expected in Fall 2026 (symptomatic) and Fall 2027 (disease-modifying). Importantly, this new formulation extends the company's intellectual property protection into the 2040s.
Annovis Bio (NYSE:ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 10, 2025, from 12:00-12:30 pm EDT at the Lotte New York Palace Hotel. The company, which develops therapies for Alzheimer's and Parkinson's disease, offers one-on-one meeting opportunities with Dr. Maccecchini through the conference portal.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, provided Q2 2025 updates on its clinical progress and financial results. The company's pivotal Phase 3 trial for early Alzheimer's disease has secured 76 U.S. clinical sites, with 38 patients already receiving treatment and approximately 200 more in screening.
Key operational highlights include the appointment of Hui Liu as Director of Biostatistics, successful presentations at AAIC 2025, and the completion of patent family transfers to crystal buntanetap. Financially, Annovis reported cash and equivalents of $17.1 million as of June 30, 2025, with reduced R&D expenses of $5.2 million and G&A expenses of $1.1 million for Q2 2025. The company's net loss per share improved to $0.32 compared to $0.44 in the same quarter last year.
Annovis Bio (NYSE: ANVS) has successfully completed the transfer of all patents to cover both the original semi-crystalline and new crystalline forms of buntanetap, its drug candidate for neurodegenerative diseases. The comprehensive IP portfolio now includes 13 patent families with protection extending to 2046.
The new crystalline form demonstrates improved solid-state stability and comparable pharmacokinetic properties to the original form, with bioequivalence confirmed through animal and human studies. The FDA has already approved the use of the crystalline form in the company's ongoing Phase 3 clinical trial for early Alzheimer's disease, which is currently active with over 75 US sites.
Annovis Bio (NYSE:ANVS) announced its participation in the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto, Canada. The company will present four scientific posters focused on their lead drug candidate, buntanetap, for Alzheimer's disease treatment.
The presentations will cover the Phase III study design for early Alzheimer's patients, details of their 6-month and 18-month pivotal clinical trial, and pharmacokinetic characterization studies of buntanetap in both animals and humans. Senior management team members, including SVP of R&D and other key scientists, will present the research findings at this premier global conference for dementia science.